IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells

• Published in: BMC cancer Vol. 13; no. 1; p. 16
• Main Authors: McCoy, Erin M, Hong, Huixian, Pruitt, Hawley C, Feng, Xu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.01.2013; BioMed Central; BMC
• Subjects: Animals; Antibodies; Antibodies, Neutralizing - pharmacology; B cells; Bone marrow; Bone metastasis; Bone resorption; Breast cancer; Breast Neoplasms - immunology; Breast Neoplasms - metabolism; Cell Line, Tumor; Cell Survival; Culture Media, Conditioned - metabolism; Cytokines; Female; Humans; Interleukin-11; Interleukin-11 - antagonists & inhibitors; Interleukin-11 - metabolism; Interleukins; Ligands; Macrophage Colony-Stimulating Factor - metabolism; Macrophages - metabolism; Metastasis; Mice; Mice, Inbred C57BL; Osteoclast; Osteoclasts (Biology); Osteoclasts - drug effects; Osteoclasts - immunology; Osteoclasts - metabolism; Osteolysis; Osteolysis - immunology; Osteolysis - metabolism; Paracrine Communication - drug effects; Physiological aspects; RANK Ligand - metabolism; RANKL; Recombinant Proteins - metabolism; Stem Cells - drug effects; Stem Cells - immunology; Stem Cells - metabolism; Studies; Time Factors; Tumors; Viral antibodies

Interleukin (IL)-11, a cytokine produced by breast cancer, has been implicated in breast cancer-induced osteolysis (bone destruction) but the mechanism(s) of action remain controversial. Some studies show that IL-11 is able to promote osteoclast formation independent of the receptor activator of NF-...